References
- S. E. Kahn, R. L. Hull, K. M. Utzschneider. "Mechanisms linking obesity to insulin resistance and type 2 diabetes", Nature, vol. 444, pp. 840-846. 2006. DOI: http://dx.doi.org/10.1038/nature05482
- G. Kloppel, M. Lohr, K. Habich, M. Oberholzer, P. U. Heitz. "Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited", Survey and Synthesis of Pathology Resesrch, vol.4, pp. 110-125. 1985.
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. "Report of the expert committee on the diagnosis and classification of diabetes mellitus", Diabetes Care, vol. 26, pp. S5-S20. 2003. https://doi.org/10.2337/diacare.26.2007.S5
- J. P. Despres, I. Lemieux. "Abdominal obesity and metabolic syndrome", Nature, vol. 444, pp. 881-887. 2006. DOI: http://dx.doi.org/10.1038/nature05488
- M. A. Nauck, E. Homberger, E. G. Siegel, R. C. Allen, R. P. Eaton, R. Ebert, W. Creutzfeldt. "Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses", The Journal of Clinical Endocrinology and Metabolism, vol. 63, pp. 492-498. 1986. DOI: http://dx.doi.org/10.1210/jcem-63-2-492
- D. J. Drucker. "The biology of incretin hormones", Cell Metabolism, vol. 3, pp. 153-165. 2006. DOI: http://dx.doi.org/10.1016/j.cmet.2006.01.004
- J. R. Ussher, D. J. Drucker. "Cardiovascular biology of the incretin system", Endocrine Reviews, vol. 33, pp. 187-215. 2012. DOI: http://dx.doi.org/10.1210/er.2011-1052
- R. Yazbeck, G. S. Howarth, C. A. Abbott. "Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?", Trends in Pharmacological Sciences, vol. 30, pp. 600-607. 2009. DOI: http://dx.doi.org/10.1016/j.tips.2009.08.003
- S. Blech, E. Ludwig-Schwellinger, E. U. Grafe-Mody, B. Withopf, K. Wagner. "The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans", Drug Metabolism and Disposition, vol. 38, pp. 667-678. 2010. DOI: http://dx.doi.org/10.1124/dmd.109.031476
- A. J. Scheen, G. Charpentier, C. J. Ostgren, A. Hellqvist, I. Gause-Nilsson. "Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus", Diabetes Metabolism Research and Reviews, vol. 26, pp. 540-549. 2010. DOI: http://dx.doi.org/10.1002/dmrr.1114
- E. J. Rhee, W. Y. Lee, K. W. Min, V. K. Shivane, A. R. Sosale, H. C. Jang, C. H. Chung, I. S. Nam-Goong, J. A. Kim, S. W. Kim; Gemigliptin Study 006 Group. "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone", Diabetes Obesity and Metabolism, vol. 15, pp. 523-530. 2013. DOI: http://dx.doi.org/10.1111/dom.12060
- Y. L. He, R. Sabo, J. Campestrini, Y. Wang, M. Ligueros-Saylan, K. C. Lasseter, S. C. Dilzer, D. Howard, W. P. Dole. "The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin", European Journal Clinical Pharmacology, vol. 63, pp. 677-686. 2007. https://doi.org/10.1007/s00228-007-0312-6
- N. Matikainen, S. Mänttäri, A. Schweizer, A. Ulvestad, D. Mills, B. E. Dunning, J. E. Foley, M. R. Taskinen. "Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes", Diabetologia, vol. 49, pp. 2049-2057. 2006. DOI: http://dx.doi.org/10.1007/s00125-006-0340-2
- B. Eliasson, D. Möller-Goede, K. Eeg-Olofsson, C. Wilson, J. Cederholm, P. Fleck, M. Diamant, M. R. Taskinen, U. Smith. "Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomized double-blind placebo-controlled study", Diabetologia, vol. 55, pp. 915-925. 2012. DOI: http://dx.doi.org/10.1007/s00125-011-2447-3
- H. C. Lee, H. M. Kim, S. Lee, K. B. Oh, H. J. Chung, B. C. Yang, K. W. Kim, P. Lee, J. K. Park, W. K. Chang. "Production of a Transgenic Pig Overexpressing Phosphoprotein Enriched in Astrocytes 15 (PEA 15)", Reproductive & Developmental Biology, vol. 35, pp. 239-245. 2011.
- H. G. Lee, H. C. Lee, S. W. Kim, P. Lee, H. J. Chung, Y. K. Lee, J. H. Han, I. S. Hwang, J. I. Yoo, Y. K. Kim, H. T. Kim, H. T. Lee, W. K. Chang, J. K. Park. "Production of recombinant human von Willebrand factor in the milk of transgenic pigs", Journal of Reproduction and Development, vol. 55, pp. 484-490. 2009. DOI: http://dx.doi.org/10.1262/jrd.20212
- L. D. Itz, F. Ishikawa, D. L. Greiner. "Humanized mice in translation biomedical research", Nature Reviews Immunology, vol. 7, pp. 118-130. 2007. https://doi.org/10.1038/nri2017
- I. H. Drespe, G. K. Polzhofer, A. S. Turner, Grauer JN. "Animal models for spinal fusion", The Spine Journal, vol. 5, pp. S209-S216. 2005. DOI: http://dx.doi.org/10.1016/j.spinee.2005.02.013
- J. K. Lunney. "Advances in swine biomedical model genomics", International Journal of Biological Sciences, vol. 3, pp. 179-184. 2007. DOI: http://dx.doi.org/10.7150/ijbs.3.179